Clinical Trial

This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

Study acronym: PRIORITY
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
* Primary objective: To describe event-free survival (EFS) in patients with stage I-III HR+/HER2- early breast cancer (EBC) who received curative surgery followed by systemic therapy. * Secondary objectives: Include assessment of relapse-free survival (RFS), distant disease-free survival (DDFS), distant relapse-free survival (DRFS), overall survival (OS), site of distant recurrence, and time-to-next treatment (TTNT), as well as evaluating the association between clinicopathologic/treatment variables and clinical outcomes. * Key inclusion criteria: Adults (≥18 years) with stage I-III HR+/HER2- invasive breast cancer who underwent curative surgery * Key exclusion criteria: HR- or HER2+ tumors, de novo stage IV, or lack of curative-intent surgery
Trial Details
NCT Number NCT07309887
Lead Sponsor Samsung Medical Center
Collaborators: Novartis
Conditions Early Breast Cancer
Enrollment 100,000 participants
Start Date 2025-12-17
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-30